Raymond James & Associates Aurinia Pharmaceuticals Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Raymond James & Associates holds 15,225 shares of AUPH stock, worth $123,626. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,225

Previous 15,700 3.03%

Holding current value

$123,626

Previous $89,000 24.72%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$5.32 - $7.33 $2,527 - $3,481	-475 Reduced 3.03%	15,225 $111,000
Q2 2024 Jul 19, 2024	SELL	$4.81 - $5.78 $9,624 - $11,565	-2,001 Reduced 11.3%	15,700 $89,000
Q1 2024 Apr 22, 2024	SELL	$4.93 - $9.31 $1,972 - $3,724	-400 Reduced 2.21%	17,701 $88,000
Q4 2023 Jan 16, 2024	BUY	$7.13 - $9.49 $8,199 - $10,913	1,150 Added 6.78%	18,101 $162,000
Q3 2023 Oct 24, 2023	BUY	$7.77 - $12.27 $36,138 - $57,067	4,651 Added 37.81%	16,951 $131,000
Q2 2023 Jul 25, 2023	BUY	$8.96 - $11.69 $4,480 - $5,845	500 Added 4.24%	12,300 $119,000
Q1 2023 Apr 14, 2023	BUY	$5.94 - $11.27 $70,092 - $132,986	11,800 New	11,800 $129,000
Q2 2022 Aug 12, 2022	SELL	$8.95 - $12.8 $101,134 - $144,640	-11,300 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$10.05 - $22.48 $113,565 - $254,024	11,300 New	11,300 $140,000
Q4 2021 Feb 08, 2022	SELL	$17.78 - $33.08 $224,028 - $416,808	-12,600 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$10.93 - $23.55 $168,212 - $362,434	-15,390 Reduced 54.98%	12,600 $279,000
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $279,900 - $406,414	27,990 New	27,990 $363,000
Q1 2021 May 14, 2021	SELL	$12.3 - $18.73 $132,225 - $201,347	-10,750 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$12.94 - $16.05 $139,105 - $172,537	10,750 New	10,750 $149,000
Q2 2020 Jul 28, 2020	SELL	$14.12 - $18.33 $585,909 - $760,603	-41,495 Closed	0 $0
Q1 2020 Apr 21, 2020	BUY	$11.34 - $21.46 $147,987 - $280,053	13,050 Added 45.88%	41,495 $602,000
Q4 2019 Feb 12, 2020	BUY	$3.88 - $21.42 $110,366 - $609,291	28,445 New	28,445 $576,000
Q3 2017 Nov 13, 2017	SELL	$5.71 - $6.9 $165,590 - $200,100	-29,000 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	29,000	29,000 $178,000

Others Institutions Holding AUPH

# of Institutions

209

Shares Held

58.7M

Call Options Held

1.14M

Put Options Held

1.51M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Aurinia Pharmaceuticals Inc. Transaction History